Trial Outcomes & Findings for A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion) (NCT NCT05850520)
NCT ID: NCT05850520
Last Updated: 2025-12-18
Results Overview
BCVA: Best-Corrected Visual Acuity; ETDRS: Early Treatment Diabetic Retinopathy Study; ETDRS letter score (ranging from 0 to 100 letters). A higher letter score means a better outcome (better visual acuity)
Recruitment status
COMPLETED
Study phase
PHASE3
Target enrollment
892 participants
Primary outcome timeframe
At Week 36
Results posted on
2025-12-18
Participant Flow
The study was conducted at 237 centers in Europe, America, Japan, and Asia-Pacific between 15-May-2023 (first participant first visit) and 07-Nov-2024 (primary completion date).
In total 1282 participants were screened, of whom 388 participants were screen failures. Overall, 892 participants were randomized and treated. Of these, 838 participants completed the treatment phase through Week 36 (primary completion date).
Participant milestones
| Measure |
Aflibercept 2q4
Participants received aflibercept 2 mg administered every 4 weeks.
|
Aflibercept 8q8/3
Participants received aflibercept 8 mg administered every 8 weeks, after 3 initial injections at 4-week intervals.
|
Aflibercept 8q8/5
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
|---|---|---|---|
|
Overall Study
STARTED
|
301
|
293
|
298
|
|
Overall Study
COMPLETED
|
287
|
278
|
273
|
|
Overall Study
NOT COMPLETED
|
14
|
15
|
25
|
Reasons for withdrawal
| Measure |
Aflibercept 2q4
Participants received aflibercept 2 mg administered every 4 weeks.
|
Aflibercept 8q8/3
Participants received aflibercept 8 mg administered every 8 weeks, after 3 initial injections at 4-week intervals.
|
Aflibercept 8q8/5
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
|---|---|---|---|
|
Overall Study
Withdrawal by Subject
|
8
|
8
|
16
|
|
Overall Study
Lost to Follow-up
|
2
|
2
|
2
|
|
Overall Study
Death
|
2
|
2
|
3
|
|
Overall Study
Adverse Event
|
2
|
0
|
1
|
|
Overall Study
Physician Decision
|
0
|
1
|
0
|
|
Overall Study
Protocol deviation
|
0
|
0
|
1
|
|
Overall Study
No information was available on whether follow-up was completed or not
|
0
|
2
|
2
|
Baseline Characteristics
A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)
Baseline characteristics by cohort
| Measure |
Aflibercept 2q4
n=301 Participants
Participants received aflibercept 2 mg administered every 4 weeks.
|
Aflibercept 8q8/3
n=293 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 3 initial injections at 4-week intervals.
|
Aflibercept 8q8/5
n=298 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
Total
n=892 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Age, Continuous
|
65.9 Years
STANDARD_DEVIATION 11.7 • n=47 Participants
|
65.8 Years
STANDARD_DEVIATION 11.5 • n=41 Participants
|
65.8 Years
STANDARD_DEVIATION 11.5 • n=88 Participants
|
65.9 Years
STANDARD_DEVIATION 11.6 • n=9 Participants
|
|
Sex: Female, Male
Female
|
144 Participants
n=47 Participants
|
136 Participants
n=41 Participants
|
146 Participants
n=88 Participants
|
426 Participants
n=9 Participants
|
|
Sex: Female, Male
Male
|
157 Participants
n=47 Participants
|
157 Participants
n=41 Participants
|
152 Participants
n=88 Participants
|
466 Participants
n=9 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
22 Participants
n=47 Participants
|
25 Participants
n=41 Participants
|
14 Participants
n=88 Participants
|
61 Participants
n=9 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
267 Participants
n=47 Participants
|
254 Participants
n=41 Participants
|
273 Participants
n=88 Participants
|
794 Participants
n=9 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
12 Participants
n=47 Participants
|
14 Participants
n=41 Participants
|
11 Participants
n=88 Participants
|
37 Participants
n=9 Participants
|
|
Race/Ethnicity, Customized
American Indian or Alaskan Native
|
0 Participants
n=47 Participants
|
0 Participants
n=41 Participants
|
2 Participants
n=88 Participants
|
2 Participants
n=9 Participants
|
|
Race/Ethnicity, Customized
Asian
|
101 Participants
n=47 Participants
|
91 Participants
n=41 Participants
|
97 Participants
n=88 Participants
|
289 Participants
n=9 Participants
|
|
Race/Ethnicity, Customized
Black or African American
|
8 Participants
n=47 Participants
|
7 Participants
n=41 Participants
|
9 Participants
n=88 Participants
|
24 Participants
n=9 Participants
|
|
Race/Ethnicity, Customized
Multiple
|
1 Participants
n=47 Participants
|
0 Participants
n=41 Participants
|
1 Participants
n=88 Participants
|
2 Participants
n=9 Participants
|
|
Race/Ethnicity, Customized
Native Hawaiian or other Pacific Islander
|
0 Participants
n=47 Participants
|
0 Participants
n=41 Participants
|
1 Participants
n=88 Participants
|
1 Participants
n=9 Participants
|
|
Race/Ethnicity, Customized
Not reported
|
13 Participants
n=47 Participants
|
22 Participants
n=41 Participants
|
11 Participants
n=88 Participants
|
46 Participants
n=9 Participants
|
|
Race/Ethnicity, Customized
White
|
178 Participants
n=47 Participants
|
173 Participants
n=41 Participants
|
177 Participants
n=88 Participants
|
528 Participants
n=9 Participants
|
PRIMARY outcome
Timeframe: At Week 36Population: Full analysis set (FAS): All participants randomly assigned to study intervention who were exposed to study intervention (active or sham injection) at least once.
BCVA: Best-Corrected Visual Acuity; ETDRS: Early Treatment Diabetic Retinopathy Study; ETDRS letter score (ranging from 0 to 100 letters). A higher letter score means a better outcome (better visual acuity)
Outcome measures
| Measure |
Aflibercept 2q4
n=301 Participants
Participants received aflibercept 2 mg administered every 4 weeks.
|
Aflibercept 8q8/3
n=293 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 3 initial injections at 4-week intervals.
|
Aflibercept 8q8/5
n=298 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
All Aflibercept HD
Pooled aflibercept 8 mg administered every 8 weeks, after 3 or 5 initial injections at 4-week intervals.
|
|---|---|---|---|---|
|
Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 36
|
17.5 Letters
Standard Error 0.7
|
17.4 Letters
Standard Error 0.7
|
18.3 Letters
Standard Error 0.6
|
—
|
SECONDARY outcome
Timeframe: From baseline to Week 36Population: Full analysis set (FAS): All participants randomly assigned to study intervention who were exposed to study intervention (active or sham injection) at least once.
Active injections refer to the number of injections that were actually administered, as opposed to the number of planned injections.
Outcome measures
| Measure |
Aflibercept 2q4
n=301 Participants
Participants received aflibercept 2 mg administered every 4 weeks.
|
Aflibercept 8q8/3
n=293 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 3 initial injections at 4-week intervals.
|
Aflibercept 8q8/5
n=298 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
All Aflibercept HD
Pooled aflibercept 8 mg administered every 8 weeks, after 3 or 5 initial injections at 4-week intervals.
|
|---|---|---|---|---|
|
Number of Active Injections From Baseline to Week 36
|
8.8 Number of active injections
Standard Error 0.0
|
6.1 Number of active injections
Standard Error 0.0
|
6.9 Number of active injections
Standard Error 0.0
|
—
|
SECONDARY outcome
Timeframe: From baseline at Week 36Population: Full analysis set (FAS): All participants randomly assigned and exposed to study intervention (active or sham injection) at least once. The Overall Number of Participants Analyzed differs from the Overall Number of Baseline Participants because only observed cases were used, excluding data after an intercurrent event (ICE) (e.g., stopping intervention or using prohibited medication before Week 36). Missing cases were not included.
Outcome measures
| Measure |
Aflibercept 2q4
n=264 Participants
Participants received aflibercept 2 mg administered every 4 weeks.
|
Aflibercept 8q8/3
n=260 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 3 initial injections at 4-week intervals.
|
Aflibercept 8q8/5
n=248 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
All Aflibercept HD
Pooled aflibercept 8 mg administered every 8 weeks, after 3 or 5 initial injections at 4-week intervals.
|
|---|---|---|---|---|
|
Participants Gaining at Least 15 Letters in BCVA From Baseline at Week 36
|
158 Participants
|
153 Participants
|
161 Participants
|
—
|
SECONDARY outcome
Timeframe: At Week 36Population: Full analysis set (FAS): All participants randomly assigned and exposed to study intervention (active or sham injection) at least once. The Overall Number of Participants Analyzed differs from the Overall Number of Baseline Participants because only observed cases were used, excluding data after an intercurrent event (ICE) (e.g., stopping intervention or using prohibited medication before Week 36). Missing cases were not included.
ETDRS letter score (ranging from 0 to 100 letters). A higher letter score means a better outcome (better visual acuity)
Outcome measures
| Measure |
Aflibercept 2q4
n=264 Participants
Participants received aflibercept 2 mg administered every 4 weeks.
|
Aflibercept 8q8/3
n=260 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 3 initial injections at 4-week intervals.
|
Aflibercept 8q8/5
n=248 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
All Aflibercept HD
Pooled aflibercept 8 mg administered every 8 weeks, after 3 or 5 initial injections at 4-week intervals.
|
|---|---|---|---|---|
|
Participants Achieving an ETDRS Letter Score of at Least 69 (Approximate 20/40 Snellen Equivalent) at Week 36
|
179 Participants
|
189 Participants
|
189 Participants
|
—
|
SECONDARY outcome
Timeframe: At Week 36Population: Full analysis set (FAS): All participants randomly assigned and exposed to study intervention (active or sham injection) at least once. The Overall Number of Participants Analyzed differs from the Overall Number of Baseline Participants because only observed cases were used, excluding data after an intercurrent event (ICE) (e.g., stopping intervention or using prohibited medication before Week 36). Missing cases were not included.
Number of participants with no retinal fluid (no IRF and no SRF) in the central subfield at Week 36
Outcome measures
| Measure |
Aflibercept 2q4
n=264 Participants
Participants received aflibercept 2 mg administered every 4 weeks.
|
Aflibercept 8q8/3
n=260 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 3 initial injections at 4-week intervals.
|
Aflibercept 8q8/5
n=247 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
All Aflibercept HD
Pooled aflibercept 8 mg administered every 8 weeks, after 3 or 5 initial injections at 4-week intervals.
|
|---|---|---|---|---|
|
Participants Having no Intraretinal Fluid (IRF) and no Sub-retinal Fluid (SRF) in the Center Subfield at Week 36
|
221 Participants
|
211 Participants
|
202 Participants
|
—
|
SECONDARY outcome
Timeframe: From baseline to Week 36Population: Full analysis set (FAS): All participants randomly assigned to study intervention who were exposed to study intervention (active or sham injection) at least once.
Outcome measures
| Measure |
Aflibercept 2q4
n=301 Participants
Participants received aflibercept 2 mg administered every 4 weeks.
|
Aflibercept 8q8/3
n=293 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 3 initial injections at 4-week intervals.
|
Aflibercept 8q8/5
n=298 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
All Aflibercept HD
Pooled aflibercept 8 mg administered every 8 weeks, after 3 or 5 initial injections at 4-week intervals.
|
|---|---|---|---|---|
|
Change From Baseline in Central Sub-field Thickness (CST) at Week 36
|
-370.8 μm
Standard Error 3.9
|
-370.9 μm
Standard Error 3.1
|
-369.5 μm
Standard Error 2.3
|
—
|
SECONDARY outcome
Timeframe: From baseline to Week 36Population: Full analysis set (FAS): All participants randomly assigned to study intervention who were exposed to study intervention (active or sham injection) at least once.
NEI-VFQ-25: National Eye Institute Visual Functioning Questionnaire-25; The NEI VFQ-25 total score ranges from 0 to 100. A higher score means a better outcome (better patient-reported visual function).
Outcome measures
| Measure |
Aflibercept 2q4
n=301 Participants
Participants received aflibercept 2 mg administered every 4 weeks.
|
Aflibercept 8q8/3
n=293 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 3 initial injections at 4-week intervals.
|
Aflibercept 8q8/5
n=298 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
All Aflibercept HD
Pooled aflibercept 8 mg administered every 8 weeks, after 3 or 5 initial injections at 4-week intervals.
|
|---|---|---|---|---|
|
Change From Baseline in NEI VFQ 25 Total Score at Week 36
|
6.27 Scores on a scale
Standard Error 0.67
|
5.91 Scores on a scale
Standard Error 0.61
|
6.92 Scores on a scale
Standard Error 0.63
|
—
|
SECONDARY outcome
Timeframe: Through Week 36Population: SAF: All participants randomly assigned to study intervention who were exposed to study intervention (active or sham injection) at least once. Analysis of the SAF was performed according to the treatment the participant actually received (as treated). The Overall Number of Participants Analyzed is not consistent with numbers provided in the Overall Number of Baseline Participants because only participants considered as completers for Week 36 were included in the analysis.
Number of participants in the aflibercept 8q8/3 and the aflibercept 8q8/5 groups who were able to maintain every 8 weeks (Q8) dosing through Week 36. Only participants who did not discontinue study intervention prior to Week 36, and were therefore considered "completers" for Week 36, were included in the analysis of this endpoint.
Outcome measures
| Measure |
Aflibercept 2q4
n=278 Participants
Participants received aflibercept 2 mg administered every 4 weeks.
|
Aflibercept 8q8/3
n=273 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 3 initial injections at 4-week intervals.
|
Aflibercept 8q8/5
n=551 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
All Aflibercept HD
Pooled aflibercept 8 mg administered every 8 weeks, after 3 or 5 initial injections at 4-week intervals.
|
|---|---|---|---|---|
|
Participants Dosed Only Q8 Through Week 36 in the 8 mg Q8 Group
|
246 Participants
|
255 Participants
|
501 Participants
|
—
|
SECONDARY outcome
Timeframe: Through Week 36Population: Safety analysis set (SAF): All participants randomly assigned to study intervention who were exposed to study intervention (active or sham injection) at least once. Analysis of the SAF was performed according to the treatment the participant actually received (as treated).
TEAEs were defined as AEs that occurred in the time frame from first injection (active or sham) to the last injection (active or sham) plus 30 days. Ocular TEAEs in study eye and non-ocular TEAEs are included (ocular TEAEs in fellow eye are excluded)
Outcome measures
| Measure |
Aflibercept 2q4
n=301 Participants
Participants received aflibercept 2 mg administered every 4 weeks.
|
Aflibercept 8q8/3
n=293 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 3 initial injections at 4-week intervals.
|
Aflibercept 8q8/5
n=298 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
All Aflibercept HD
n=591 Participants
Pooled aflibercept 8 mg administered every 8 weeks, after 3 or 5 initial injections at 4-week intervals.
|
|---|---|---|---|---|
|
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Through Weeks 36
Number of participants with TEAEs
|
188 Participants
|
184 Participants
|
176 Participants
|
360 Participants
|
|
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Through Weeks 36
Number of participants with TESAEs
|
32 Participants
|
23 Participants
|
26 Participants
|
49 Participants
|
SECONDARY outcome
Timeframe: From baseline through Week 36Population: Pharmacokinetic analysis set (PKS): All participants randomly assigned to study intervention with at least one non-missing PK result after the first dose of study intervention.
Total aflibercept is the sum of free and adjusted bound aflibercept.
Outcome measures
| Measure |
Aflibercept 2q4
n=299 Participants
Participants received aflibercept 2 mg administered every 4 weeks.
|
Aflibercept 8q8/3
n=290 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 3 initial injections at 4-week intervals.
|
Aflibercept 8q8/5
n=294 Participants
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
All Aflibercept HD
Pooled aflibercept 8 mg administered every 8 weeks, after 3 or 5 initial injections at 4-week intervals.
|
|---|---|---|---|---|
|
Systemic Exposure to Aflibercept as Assessed by Plasma Concentrations of Free, Adjusted Bound and Total Aflibercept From Baseline Through Weeks 36
Week 4
|
91.6 ng/mL
Geometric Coefficient of Variation 55.82
|
281.8 ng/mL
Geometric Coefficient of Variation 52.16
|
270.7 ng/mL
Geometric Coefficient of Variation 63.78
|
—
|
|
Systemic Exposure to Aflibercept as Assessed by Plasma Concentrations of Free, Adjusted Bound and Total Aflibercept From Baseline Through Weeks 36
Week 12
|
151.5 ng/mL
Geometric Coefficient of Variation 56.99
|
451.7 ng/mL
Geometric Coefficient of Variation 58.83
|
452.6 ng/mL
Geometric Coefficient of Variation 57.04
|
—
|
|
Systemic Exposure to Aflibercept as Assessed by Plasma Concentrations of Free, Adjusted Bound and Total Aflibercept From Baseline Through Weeks 36
Week 16
|
241.6 ng/mL
Geometric Coefficient of Variation 48.40
|
470.5 ng/mL
Geometric Coefficient of Variation 58.24
|
729.0 ng/mL
Geometric Coefficient of Variation 43.82
|
—
|
|
Systemic Exposure to Aflibercept as Assessed by Plasma Concentrations of Free, Adjusted Bound and Total Aflibercept From Baseline Through Weeks 36
Week 24
|
165.6 ng/mL
Geometric Coefficient of Variation 58.72
|
179.8 ng/mL
Geometric Coefficient of Variation 73.07
|
202.5 ng/mL
Geometric Coefficient of Variation 80.94
|
—
|
|
Systemic Exposure to Aflibercept as Assessed by Plasma Concentrations of Free, Adjusted Bound and Total Aflibercept From Baseline Through Weeks 36
Week 36
|
167.8 ng/mL
Geometric Coefficient of Variation 58.81
|
366.0 ng/mL
Geometric Coefficient of Variation 57.87
|
313.8 ng/mL
Geometric Coefficient of Variation 97.30
|
—
|
Adverse Events
Aflibercept 2q4
Serious events: 32 serious events
Other events: 188 other events
Deaths: 2 deaths
Aflibercept 8q8/3
Serious events: 23 serious events
Other events: 184 other events
Deaths: 2 deaths
Aflibercept 8q8/5
Serious events: 26 serious events
Other events: 176 other events
Deaths: 3 deaths
All Aflibercept 8 mg
Serious events: 49 serious events
Other events: 360 other events
Deaths: 5 deaths
Serious adverse events
| Measure |
Aflibercept 2q4
n=301 participants at risk
Participants received aflibercept 2mg administered every 4 weeks.
|
Aflibercept 8q8/3
n=293 participants at risk
Participants received aflibercept 8 mg administered every 8 weeks, after 3 initial injections at 4-week intervals.
|
Aflibercept 8q8/5
n=298 participants at risk
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
All Aflibercept 8 mg
n=591 participants at risk
Pooled aflibercept 8 mg administered every 8 weeks, after 3 or 5 initial injections at 4-week intervals.
|
|---|---|---|---|---|
|
Blood and lymphatic system disorders
Pancytopenia
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Acute myocardial infarction
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Atrial fibrillation
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Bradycardia
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Coronary artery disease
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Myocardial infarction
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Acute coronary syndrome
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Ear and labyrinth disorders
Vertigo
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Endocrine disorders
Primary hyperaldosteronism
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Cataract
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Retinal artery occlusion
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Retinal detachment
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Retinal vasculitis
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Retinal vein occlusion
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Visual acuity reduced
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Macular hole
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Hiatus hernia
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Small intestinal obstruction
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Lower gastrointestinal haemorrhage
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Femoral hernia incarcerated
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders
Incarcerated hernia
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders
Oedema
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders
General physical health deterioration
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Hepatobiliary disorders
Cholecystitis acute
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Hepatobiliary disorders
Cholecystitis chronic
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Hepatobiliary disorders
Hepatic cyst
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Immune system disorders
Anaphylactic reaction
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Bronchitis
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Diverticulitis
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Endophthalmitis
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Gastroenteritis
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Herpes zoster
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Osteomyelitis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Pneumonia
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Pneumonia parainfluenzae viral
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Pneumonia pseudomonal
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Sepsis
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Infectious pleural effusion
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
COVID-19
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Brain herniation
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Cartilage injury
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Humerus fracture
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Rib fracture
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Snake bite
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Subdural haematoma
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Tendon rupture
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Postoperative thoracic procedure complication
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Skin laceration
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Pelvic fracture
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Procedural pain
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Blood urine present
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Hypoglycaemia
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Type 2 diabetes mellitus
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Haemarthrosis
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Osteoarthritis
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Intervertebral disc compression
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon cancer
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal carcinoma
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer metastatic
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Cerebral infarction
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer stage II
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectal cancer
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of lung
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
T-cell lymphoma
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung neoplasm malignant
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Cerebrovascular accident
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic neoplasm
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Cerebellar infarction
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Epilepsy
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Haemorrhage intracranial
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Sciatica
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Lacunar infarction
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Cerebellar stroke
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Atypical migraine
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Psychiatric disorders
Anxiety
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Psychiatric disorders
Mental status changes
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Calculus bladder
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Nephrolithiasis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Diabetic nephropathy
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Urinary tract discomfort
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Reproductive system and breast disorders
Benign prostatic hyperplasia
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Reproductive system and breast disorders
Uterine haemorrhage
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Reproductive system and breast disorders
Pelvic organ prolapse
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory failure
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Surgical and medical procedures
Medical induction of coma
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Giant cell arteritis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Peripheral artery occlusion
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Hypertensive emergency
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
Other adverse events
| Measure |
Aflibercept 2q4
n=301 participants at risk
Participants received aflibercept 2mg administered every 4 weeks.
|
Aflibercept 8q8/3
n=293 participants at risk
Participants received aflibercept 8 mg administered every 8 weeks, after 3 initial injections at 4-week intervals.
|
Aflibercept 8q8/5
n=298 participants at risk
Participants received aflibercept 8 mg administered every 8 weeks, after 5 initial injections at 4-week intervals.
|
All Aflibercept 8 mg
n=591 participants at risk
Pooled aflibercept 8 mg administered every 8 weeks, after 3 or 5 initial injections at 4-week intervals.
|
|---|---|---|---|---|
|
General disorders
Injection site irritation
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders
Injection site pain
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders
Malaise
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders
Mass
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders
Oedema
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders
Oedema peripheral
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.4%
4/293 • Number of events 4 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
4/591 • Number of events 4 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders
Pain
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders
Pyrexia
|
1.3%
4/301 • Number of events 4 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders
Peripheral swelling
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders
Sensation of foreign body
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders
Application site hypersensitivity
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Hepatobiliary disorders
Biliary colic
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Hepatobiliary disorders
Cholelithiasis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Hepatobiliary disorders
Hepatic cyst
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Hepatobiliary disorders
Hepatic steatosis
|
1.3%
4/301 • Number of events 4 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/298 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Hepatobiliary disorders
Metabolic dysfunction-associated liver disease
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Immune system disorders
Drug hypersensitivity
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Immune system disorders
Hypersensitivity
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Immune system disorders
Multiple allergies
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Immune system disorders
Seasonal allergy
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Immune system disorders
Allergy to arthropod sting
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Immune system disorders
Allergy to chemicals
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Acute sinusitis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Atypical pneumonia
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Bronchitis
|
1.00%
3/301 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/293 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
4/591 • Number of events 4 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Chronic hepatitis C
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Chronic sinusitis
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Conjunctivitis
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/293 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.85%
5/591 • Number of events 6 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Conjunctivitis viral
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Cystitis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Diverticulitis
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Epididymitis
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Erysipelas
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Fungal infection
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Fungal skin infection
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Gastroenteritis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Gastroenteritis viral
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Gingivitis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Herpes simplex
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Herpes zoster
|
1.00%
3/301 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/298 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Hordeolum
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Influenza
|
2.0%
6/301 • Number of events 6 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.4%
4/293 • Number of events 4 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.85%
5/591 • Number of events 5 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Localised infection
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Lower respiratory tract infection
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Nasopharyngitis
|
3.0%
9/301 • Number of events 9 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
5.1%
15/293 • Number of events 18 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
4.7%
14/298 • Number of events 15 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
4.9%
29/591 • Number of events 33 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Oral candidiasis
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Otitis externa
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Periodontitis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Pharyngitis
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.4%
4/293 • Number of events 4 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
4/591 • Number of events 4 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Pneumonia
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Pulpitis dental
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Rhinitis
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Sinusitis
|
1.00%
3/301 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/298 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
4/591 • Number of events 4 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Tinea cruris
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Tinea pedis
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Tonsillitis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Tooth abscess
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Upper respiratory tract infection
|
1.7%
5/301 • Number of events 5 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/293 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/298 • Number of events 4 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
6/591 • Number of events 7 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Urinary tract infection
|
3.3%
10/301 • Number of events 10 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.4%
4/293 • Number of events 4 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
3.4%
10/298 • Number of events 10 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
2.4%
14/591 • Number of events 14 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Vaginal infection
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Viral infection
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Viral upper respiratory tract infection
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Wound infection
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Tooth infection
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Coronavirus infection
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Escherichia urinary tract infection
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Helicobacter infection
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Blood bilirubin increased
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Blood cholesterol increased
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Blood creatine increased
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Blood creatine phosphokinase increased
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
4/591 • Number of events 4 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Asymptomatic bacteriuria
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Enterocolitis infectious
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Abdominal abscess
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Respiratory syncytial virus infection
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Respiratory tract infection
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Herpes dermatitis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Viral rhinitis
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Oral herpes
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
Infected dermal cyst
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Infections and infestations
COVID-19
|
1.7%
5/301 • Number of events 5 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
4.1%
12/293 • Number of events 12 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
2.0%
6/298 • Number of events 6 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
3.0%
18/591 • Number of events 18 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Corneal abrasion
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Fall
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/298 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Foot fracture
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Foreign body in eye
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Hand fracture
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Injury corneal
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Tendon injury
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Wrist fracture
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Muscle strain
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Contusion
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Postoperative thoracic procedure complication
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Skin laceration
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Joint injury
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Limb injury
|
0.33%
1/301 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Upper limb fracture
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Procedural pain
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Bone contusion
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Post procedural swelling
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Procedural nausea
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Injection related reaction
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Meniscus injury
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Oral contusion
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Injury, poisoning and procedural complications
Intra-ocular injection complication
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.7%
5/293 • Number of events 5 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.85%
5/591 • Number of events 5 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Alanine aminotransferase increased
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Aspartate aminotransferase increased
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Bilirubin conjugated increased
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Blood albumin increased
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Blood and lymphatic system disorders
Anaemia
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Blood and lymphatic system disorders
Iron deficiency anaemia
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Blood and lymphatic system disorders
Lymphocytosis
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Blood and lymphatic system disorders
Monocytosis
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Blood and lymphatic system disorders
Neutrophilia
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Blood and lymphatic system disorders
Blood loss anaemia
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Aortic valve incompetence
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Arrhythmia
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Arteriosclerosis coronary artery
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Atrial fibrillation
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Atrial tachycardia
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Atrioventricular block first degree
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Bradycardia
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Bundle branch block left
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Bundle branch block right
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Coronary artery disease
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Hypertensive heart disease
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Mitral valve incompetence
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Myocardial infarction
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Palpitations
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Sinus bradycardia
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Tachycardia
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/298 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Tricuspid valve incompetence
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Ventricular extrasystoles
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Left ventricular hypertrophy
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Left ventricular enlargement
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Cardiac disorders
Ventricular dyssynchrony
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Congenital, familial and genetic disorders
Thalassaemia
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Congenital, familial and genetic disorders
Factor V Leiden mutation
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Ear and labyrinth disorders
Deafness
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Ear and labyrinth disorders
Ear pain
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Ear and labyrinth disorders
Presbyacusis
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Ear and labyrinth disorders
Tinnitus
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Ear and labyrinth disorders
Vertigo
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.3%
4/298 • Number of events 4 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
6/591 • Number of events 6 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Ear and labyrinth disorders
Vertigo positional
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Ear and labyrinth disorders
Ear inflammation
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Endocrine disorders
Autoimmune thyroiditis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Endocrine disorders
Thyroid mass
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Aphakia
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Blepharitis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Blepharospasm
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Blindness
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Borderline glaucoma
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Cataract
|
3.0%
9/301 • Number of events 9 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.7%
5/293 • Number of events 5 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
3.0%
9/298 • Number of events 9 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
2.4%
14/591 • Number of events 14 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Cataract cortical
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Cataract nuclear
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Chalazion
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Ciliary muscle spasm
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Conjunctival haemorrhage
|
2.0%
6/301 • Number of events 7 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
3.4%
10/293 • Number of events 10 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
2.3%
7/298 • Number of events 7 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
2.9%
17/591 • Number of events 17 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Conjunctival irritation
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Conjunctival oedema
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Conjunctivitis allergic
|
1.3%
4/301 • Number of events 5 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/293 • Number of events 4 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.85%
5/591 • Number of events 6 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Corneal infiltrates
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Corneal scar
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Diabetic retinopathy
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Dry eye
|
2.0%
6/301 • Number of events 6 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.4%
4/293 • Number of events 4 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.7%
5/298 • Number of events 5 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.5%
9/591 • Number of events 9 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Eye inflammation
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Eye irritation
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Eye pain
|
1.00%
3/301 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.7%
5/293 • Number of events 5 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.3%
4/298 • Number of events 4 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.5%
9/591 • Number of events 9 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Eye swelling
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Glaucoma
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.4%
4/293 • Number of events 4 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.85%
5/591 • Number of events 5 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Iritis
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Keratitis
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Lenticular opacities
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Macular degeneration
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Macular oedema
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Maculopathy
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Ocular hyperaemia
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Ocular hypertension
|
1.3%
4/301 • Number of events 4 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.4%
4/293 • Number of events 4 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
6/591 • Number of events 6 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Open angle glaucoma
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Optic atrophy
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Optic nerve cupping
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Posterior capsule opacification
|
0.33%
1/301 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Presbyopia
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Pterygium
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Punctate keratitis
|
1.7%
5/301 • Number of events 5 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.4%
4/293 • Number of events 5 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
6/591 • Number of events 8 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Retinal artery embolism
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Retinal artery occlusion
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Retinal degeneration
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Retinal exudates
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
4/591 • Number of events 5 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Retinal haemorrhage
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
4/591 • Number of events 5 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Retinal ischaemia
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Retinal oedema
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 4 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Retinal pigment epitheliopathy
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Retinal tear
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Retinal vascular disorder
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Retinal vein occlusion
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
4/591 • Number of events 4 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Swelling of eyelid
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Uveitis
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Vision blurred
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Visual acuity reduced
|
1.00%
3/301 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
4.1%
12/293 • Number of events 12 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
2.3%
7/298 • Number of events 7 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
3.2%
19/591 • Number of events 19 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Visual field defect
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Visual impairment
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Vitreous detachment
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
2.7%
8/293 • Number of events 8 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
3.0%
9/298 • Number of events 11 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
2.9%
17/591 • Number of events 19 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Vitreous floaters
|
1.00%
3/301 • Number of events 4 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.4%
4/293 • Number of events 4 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
6/591 • Number of events 6 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Vitreous haemorrhage
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/293 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.85%
5/591 • Number of events 5 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Vitreous opacities
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Xerophthalmia
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Macular hole
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Foreign body sensation in eyes
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Conjunctival hyperaemia
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Eye pruritus
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Ocular discomfort
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Detachment of retinal pigment epithelium
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Keratic precipitates
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Anterior chamber cell
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Allergic keratitis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Cystoid macular oedema
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Eyelid disorder
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Optic neuropathy
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Corneal disorder
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Anterior chamber disorder
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Retinal drusen
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Epiretinal membrane
|
2.0%
6/301 • Number of events 6 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/293 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
2.3%
7/298 • Number of events 7 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.7%
10/591 • Number of events 10 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Meibomian gland dysfunction
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Macular ischaemia
|
0.33%
1/301 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Normal tension glaucoma
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Dysmetropsia
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Narrow anterior chamber angle
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Vitreoretinal traction syndrome
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 4 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 4 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Dry age-related macular degeneration
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Retinal collateral vessels
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Conjunctival suffusion
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Eye disorders
Macular thickening
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.7%
5/293 • Number of events 5 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.85%
5/591 • Number of events 5 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Abdominal pain
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Chronic gastritis
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Crohn's disease
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Dental caries
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Diarrhoea
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Diverticulum intestinal
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Duodenal ulcer
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Dysphagia
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Food poisoning
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Gastritis
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Gastrooesophageal reflux disease
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Gastrointestinal disorder
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Glossitis
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Haemorrhoids
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Irritable bowel syndrome
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Mouth ulceration
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Nausea
|
1.3%
4/301 • Number of events 4 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.4%
4/293 • Number of events 5 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/298 • Number of events 4 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.2%
7/591 • Number of events 9 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Oesophagitis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Pancreatic disorder
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Periodontal disease
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Stomatitis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Toothache
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Vomiting
|
1.7%
5/301 • Number of events 6 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Gastrointestinal disorders
Large intestine polyp
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders
Application site irritation
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders
Asthenia
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders
Chest pain
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.4%
4/293 • Number of events 4 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.85%
5/591 • Number of events 5 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders
Chills
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders
Cyst
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders
Fatigue
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders
Gait disturbance
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders
Hernia
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders
Influenza like illness
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
4/591 • Number of events 4 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
General disorders
Injection site bruising
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Blood creatinine decreased
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Blood glucose increased
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Blood iron decreased
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Blood potassium increased
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Blood pressure diastolic increased
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Blood pressure increased
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.7%
5/293 • Number of events 6 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.2%
7/591 • Number of events 8 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Blood pressure systolic increased
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Blood triglycerides increased
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Blood urea increased
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Blood uric acid increased
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Electrocardiogram QT prolonged
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Glucose urine
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Glycosylated haemoglobin increased
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/293 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.7%
5/298 • Number of events 5 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.4%
8/591 • Number of events 8 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Haematocrit decreased
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Haematocrit increased
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Blood urine present
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Haemoglobin decreased
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Haemoglobin increased
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Intraocular pressure decreased
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Intraocular pressure increased
|
1.7%
5/301 • Number of events 11 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
5.5%
16/293 • Number of events 22 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
5.0%
15/298 • Number of events 25 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
5.2%
31/591 • Number of events 47 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Liver function test abnormal
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Low density lipoprotein increased
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Mean cell haemoglobin decreased
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Mean cell volume abnormal
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Monocyte count increased
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Neutrophil count increased
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Platelet count decreased
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Protein total increased
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Red blood cell count decreased
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Weight decreased
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Weight increased
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
White blood cell count increased
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
White blood cells urine positive
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Urinary sediment present
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Red blood cells urine
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Creatinine urine increased
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Protein urine present
|
1.00%
3/301 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Urine protein/creatinine ratio increased
|
1.00%
3/301 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Creatinine urine decreased
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Optic nerve cup/disc ratio increased
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Urine ketone body present
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Bacterial test positive
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Blood alkaline phosphatase increased
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Intraocular pressure test abnormal
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Urine analysis abnormal
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Urobilinogen urine increased
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Investigations
Liver function test increased
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Acidosis
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Dehydration
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Diabetes mellitus
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Diabetic ketoacidosis
|
0.33%
1/301 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Diabetic ketosis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Glucose tolerance impaired
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Gout
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Hypercholesterolaemia
|
1.7%
5/301 • Number of events 5 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/293 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
2.3%
7/298 • Number of events 7 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.7%
10/591 • Number of events 10 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Hyperkalaemia
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Hypertriglyceridaemia
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Hyperuricaemia
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Hypervolaemia
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Hypoglycaemia
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
4/591 • Number of events 4 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Obesity
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Overweight
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Vitamin D deficiency
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Metabolic syndrome
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Dyslipidaemia
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/298 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Lipid metabolism disorder
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Vitamin B complex deficiency
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Hyperlipidaemia
|
2.3%
7/301 • Number of events 7 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/298 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
4/591 • Number of events 4 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Metabolism and nutrition disorders
Type 2 diabetes mellitus
|
1.3%
4/301 • Number of events 5 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/298 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
2.0%
6/301 • Number of events 6 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/293 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.3%
4/298 • Number of events 4 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.2%
7/591 • Number of events 7 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Arthritis
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 4 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
1.3%
4/301 • Number of events 4 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/298 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.85%
5/591 • Number of events 5 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Bursitis
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Dupuytren's contracture
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Joint effusion
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Joint swelling
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Muscle disorder
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Myositis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Osteoarthritis
|
1.00%
3/301 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/298 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Osteoporosis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/293 • Number of events 4 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.85%
5/591 • Number of events 6 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Periarthritis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Plantar fasciitis
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Rheumatoid arthritis
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/293 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Rotator cuff syndrome
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Scoliosis
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Spinal osteoarthritis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Systemic lupus erythematosus
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Tenosynovitis
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal stiffness
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Foot deformity
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Intervertebral disc degeneration
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Tendon pain
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Rheumatic disorder
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Musculoskeletal and connective tissue disorders
Vertebral lateral recess stenosis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Basal cell carcinoma
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign breast neoplasm
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Leiomyoma
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Cerebellar infarction
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lipoma
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to lymph nodes
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Seborrhoeic keratosis
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of skin
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Uterine leiomyoma
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cancer fatigue
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Amnesia
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Carotid artery stenosis
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Cerebral infarction
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Cerebrovascular disorder
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Dementia
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Dementia Alzheimer's type
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Diabetic neuropathy
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Dizziness
|
1.3%
4/301 • Number of events 5 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.3%
4/298 • Number of events 4 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
4/591 • Number of events 4 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Epilepsy
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Facial paralysis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Headache
|
1.7%
5/301 • Number of events 14 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
2.0%
6/293 • Number of events 6 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
2.0%
6/298 • Number of events 8 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
2.0%
12/591 • Number of events 14 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Hypoaesthesia
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Memory impairment
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Normal pressure hydrocephalus
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Paraesthesia
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Post herpetic neuralgia
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Sciatica
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Syncope
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/298 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Vertebral artery stenosis
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Carotid artery occlusion
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Cervical radiculopathy
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Lumbar radiculopathy
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Cognitive disorder
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Peripheral nerve palsy
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Nervous system disorders
Carotid arteriosclerosis
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Psychiatric disorders
Anxiety
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Psychiatric disorders
Depression
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Psychiatric disorders
Euphoric mood
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Psychiatric disorders
Insomnia
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Psychiatric disorders
Sleep disorder
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Psychiatric disorders
Tension
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Dysuria
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Haematuria
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Nephrolithiasis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Nephropathy
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Nocturia
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Proteinuria
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/293 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Urinary incontinence
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Urinary retention
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Urine abnormality
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Cystitis noninfective
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Chronic kidney disease
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Acute kidney injury
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Renal and urinary disorders
Ureterolithiasis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Reproductive system and breast disorders
Benign prostatic hyperplasia
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Reproductive system and breast disorders
Gynaecomastia
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Reproductive system and breast disorders
Infertility
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Reproductive system and breast disorders
Ovarian cyst
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Reproductive system and breast disorders
Prostatitis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Reproductive system and breast disorders
Uterine haemorrhage
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Reproductive system and breast disorders
Prostatomegaly
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Reproductive system and breast disorders
Heavy menstrual bleeding
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Reproductive system and breast disorders
Pelvic organ prolapse
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Respiratory, thoracic and mediastinal disorders
Asthma
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Respiratory, thoracic and mediastinal disorders
Bronchitis chronic
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
1.3%
4/301 • Number of events 4 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.4%
4/293 • Number of events 4 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
6/591 • Number of events 6 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.33%
1/301 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.51%
3/591 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Respiratory, thoracic and mediastinal disorders
Rhinitis allergic
|
0.66%
2/301 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Respiratory, thoracic and mediastinal disorders
Rhinorrhoea
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Respiratory, thoracic and mediastinal disorders
Sleep apnoea syndrome
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Respiratory, thoracic and mediastinal disorders
Throat irritation
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary mass
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Respiratory, thoracic and mediastinal disorders
Paranasal sinus mucosal hypertrophy
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
1.0%
3/293 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
4/591 • Number of events 4 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Skin and subcutaneous tissue disorders
Acne
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Skin and subcutaneous tissue disorders
Actinic keratosis
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Skin and subcutaneous tissue disorders
Dermatitis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Skin and subcutaneous tissue disorders
Dermatitis contact
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Skin and subcutaneous tissue disorders
Dry skin
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Skin and subcutaneous tissue disorders
Eczema
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 3 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Skin and subcutaneous tissue disorders
Eczema asteatotic
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Skin and subcutaneous tissue disorders
Hyperkeratosis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Skin and subcutaneous tissue disorders
Miliaria
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Skin and subcutaneous tissue disorders
Skin irritation
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Skin and subcutaneous tissue disorders
Skin ulcer
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Skin and subcutaneous tissue disorders
Stasis dermatitis
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Skin and subcutaneous tissue disorders
Urticaria
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.67%
2/298 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Skin and subcutaneous tissue disorders
Skin swelling
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Skin and subcutaneous tissue disorders
Cutaneous symptom
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Social circumstances
Menopause
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Surgical and medical procedures
Spinal fusion surgery
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Surgical and medical procedures
Skin neoplasm excision
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Surgical and medical procedures
Tooth extraction
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Aortic aneurysm
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Arteriosclerosis
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.68%
2/293 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Blood pressure fluctuation
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Embolism venous
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Essential hypertension
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Hypertension
|
3.3%
10/301 • Number of events 12 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
6.5%
19/293 • Number of events 20 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
6.7%
20/298 • Number of events 22 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
6.6%
39/591 • Number of events 42 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Hypotension
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Peripheral vascular disorder
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Thrombophlebitis
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Vein disorder
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Deep vein thrombosis
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Vascular shunt
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/293 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
2/591 • Number of events 2 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Aortic dilatation
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Peripheral arterial occlusive disease
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Aortic arteriosclerosis
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Brachiocephalic arteriosclerosis
|
0.00%
0/301 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.34%
1/298 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.17%
1/591 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Vein rupture
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
|
Vascular disorders
Scalp haematoma
|
0.33%
1/301 • Number of events 1 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/293 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/298 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
0.00%
0/591 • Adverse events (AEs) were collected from the first injection (active or sham) up to the last injection (active or sham) plus 30 days. AE reporting for the all-cause mortality considers all deaths that occurred at any time during the study, up to cut-off date for the primary completion analysis 07 NOV 2024 (approximately 36 weeks).
Ocular treatment-emergent adverse events (TEAEs) in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place